Research Article
MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes
Table 3
Survival analysis of miRSNPs in mTOR pathway in 134 patients with stage III small cell lung cancer.
| Gene SNP | Model | 5yOS | HR (95% CI) | Log-rank | HR (95% CI) (adjusted) | adjusted | |
| VEGFA rs10434 | DOM | GG (90) | 37.9% | 0.739 (0.424–1.288) | 0.284 | 0.830 (0.468–1.472) | 0.523 | 0.584 | GA + AA (44) | 39.6% | DDIT4 rs1053639 | DOM | AA (80) | 35.1% | 1.042 (0.622–1.744) | 0.877 | 0.970 (0.573–1.639) | 0.908 | 0.709 | AT + TT (54) | 42.1% | MAPK1 rs1063311 | DOM | CC (97) | 36.8% | 0.694 (0.366–1.315) | 0.260 | 0.542 (0.308–0.953) | 0.101 | 0.219 | CT + TT (34) | 41.7% | PTEN rs11202607 | ADD | CC (111) | 35.9% | 0.607 (0.260–1.416) | 0.243 | 0.493 (0.208–1.169) | 0.108 | 0.225 | CT (22) | 58.5% | PIK3R1 rs12755 | REC | CA + CC (123) | 36.2% | 0.360 (0.088–1.475) | 0.155 | 0.242 (0.058–1.010) | 0.052 | 0.161 | AA (10) | 70.0% | MTOR rs2536 | ADD | TT (108) | 43.1% | 1.978 (1.087–3.600) | 0.026 | 2.039 (1.117–3.720) | 0.020 | 0.103 | TC (22) | 21.2% | VEGFA rs3025039 | DOM | CC (80) | 42.9% | 1.127 (0.666–1.908) | 0.655 | 1.185 (0.687–2.044) | 0.541 | 0.592 | CT + TT (52) | 33.4% | PIK3R1 rs3756668 | REC | GA + GG (109) | 34.0% | 0.362 (0.155–0.845) | 0.014 | 0.341 (0.146–0.797) | 0.013 | 0.103 | AA (23) | 49.5% | PTEN rs701848 | DOM | TT (47) | 23.5% | 0.885 (0.504–1.556) | 0.672 | 0.759 (0.423–1.362) | 0.356 | 0.488 | TC + CC (85) | 40.8% |
|
|
Adjusted for age, gender, Karnofsky performance score (KPS), smoking history, and Charlson comorbidity index (CCI). miRSNPs: miRNA-related single nucleotide polymorphisms; OS: overall survival; HR: hazard ratio; CI: confidence interval. Reference sequences: VEGFA GenBank NG_008732; DDIT4 GenBank NM_019058; MAPK1 GenBank NG_023054; PTEN GenBank NG_007466; PIK3R1 GenBank NG_012849; MTOR GenBank NG_033239.
|